Media coverage about USANA Health Sciences (NYSE:USNA) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. USANA Health Sciences earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.503032324824 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Shares of USANA Health Sciences (NYSE:USNA) opened at $74.35 on Thursday. USANA Health Sciences has a 1 year low of $52.55 and a 1 year high of $74.90. The company has a market capitalization of $1,760.00, a P/E ratio of 19.66 and a beta of 1.08.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, October 24th. The company reported $1.02 EPS for the quarter, beating the consensus estimate of $0.91 by $0.11. USANA Health Sciences had a return on equity of 26.38% and a net margin of 8.79%. The firm had revenue of $261.77 million for the quarter, compared to analysts’ expectations of $259.52 million. During the same period last year, the firm earned $2.40 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. research analysts forecast that USANA Health Sciences will post 3.7 EPS for the current year.

Several research firms recently commented on USNA. BidaskClub upgraded USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Pivotal Research raised their target price on USANA Health Sciences from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, October 25th.

In other USANA Health Sciences news, Director Myron W. Wentz sold 40,000 shares of the stock in a transaction on Tuesday, October 3rd. The stock was sold at an average price of $57.54, for a total transaction of $2,301,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Global Ltd Gull sold 45,216 shares of the stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $66.44, for a total value of $3,004,151.04. Following the transaction, the insider now directly owns 11,694,053 shares of the company’s stock, valued at $776,952,881.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 663,752 shares of company stock worth $43,712,972. 53.20% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: “USANA Health Sciences (USNA) Earns Media Sentiment Score of 0.04” was posted by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.